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Introduction
Neuronal compensation is widely assumed to account for
the dissociation between brain pathology and (absence of)
behavioural change during the prodromal and early stages
of neurodegenerative conditions such as Huntington’s dis-
ease and Alzheimer’s disease (Barulli and Stern, 2013;
Dennis and Cabeza, 2013; Scheller et al., 2014). Despite
varying degrees of structural loss, patients demonstrate a
level of performance during many tasks that is indistin-
guishable from their earlier performance, and is often simi-
lar to that of a normal population (Obeso et al., 2004;
Malejko et al., 2014; Papoutsi et al., 2014; Kloppel and
Gregory, 2015). Performance is maintained until patho-
logical factors progress and performance levels begin to
deteriorate. However, neuronal mechanisms that underlie
such postulated compensation in neurodegeneration are
poorly understood due to the complexity in deﬁning what
compensation actually is and how it can be measured.
The characterization of compensation in neurodegenera-
tion that we present here is derived from theoretical models
of compensation in healthy ageing and Alzheimer’s disease
(Lo¨vde´n et al., 2010; Barulli and Stern, 2013; Reuter-
Lorenz and Park, 2014). The complementary processes
that may account for improved performance in the presence
of structural degeneration include utilization of brain re-
serve and/or cognitive reserve, brain maintenance, and
compensation (Barulli and Stern, 2013). Brain reserve de-
scribes the differences in brain size and structure that may
support maintenance of function during ageing (or path-
ology). Cognitive reserve conversely is the preservation of
functional efﬁciency and capacity despite neuronal degen-
eration until a critical point is reached. It is associated with
lifestyle factors, including education and socio-economic
status, which modulate the cognitive effects of ageing
(Stern, 2006; Barulli and Stern, 2013). It is suggested that
cognitive reserve comprises neuronal reserve, which ac-
counts for the increased efﬁciency; and neural compensa-
tion where task-unrelated regions are recruited to perform
a function (Stern, 2006). This is consistent with the concept
of ﬂexibility that, as a proxy for functional capacity and
intelligence, describes the brain’s ability to optimize per-
formance to cope with existing demands; these changes
eventually leading to more permanent changes in the
brain (Lo¨vde´n et al., 2010).
Compensation may also represent processes where acti-
vation within existing network regions increases. This is
compatible with brain maintenance, whereby susceptibility
to ageing (or pathology) can impact onset of cognitive de-
cline, and other models of compensation, which promote
the concept of augmented activation in existing networks
(Barulli and Stern, 2013). The Scaffolding Theory of Aging
and Cognition (STAC) in particular, proposes that both
brain structure and function deteriorate with age, but that
compensatory scaffolding counteracts adverse effects of
neuronal and functional decline (Reuter-Lorenz and Park,
2014). This is congruent with changes that occur in neuro-
degenerative disease where structure degenerates, but per-
formance is maintained due to compensatory changes in
brain activity. Furthermore, STAC suggests that once de-
terioration becomes suitably severe, compensatory effects
dissipate; just as functional compensation declines as neu-
rodegenerative pathology progresses and structural degen-
eration becomes too severe.
In characterizing compensation, we suppose that in a
subset of prodromal patients with pathological loss of
brain tissue there is reorganization within the brain that
enables them to function at the same level as those without
disease-related neuronal loss. As mentioned above, compen-
sation may present as increased activation in a task-relevant
brain region or recruitment of a brain region not typically
associated with the function or network being tested. The
latter is difﬁcult to assess as there may be reasons for
increased activity other than compensation. Furthermore,
compensation may simply represent a situation whereby
the rate of disease-related neuronal dysfunction is slowed
over time, supporting the idea of preserved cognitive func-
tion. Here, we will focus on the notion that evidence of
compensation in neurodegenerative disease is present when
behaviour in patients is more similar to that of the normal
population due to changes in brain activity and in the pres-
ence of structural degeneration (Barulli and Stern, 2013;
Scheller et al., 2014).
If compensation is deﬁned as a lack of change in behav-
iour despite progressive brain pathology, then it is the ab-
sence or decreased severity of a behavioural deﬁcit that
needs to be measured as an outcome; this is challenging.
In standard experimental paradigms, task-related changes
in behaviour are used to explain changes in brain activity.
Behavioural changes can be accounted for by concomitant
changes in brain activity that ultimately differentiate the
group(s) under investigation. When ‘absence’ of behav-
ioural changes is the outcome variable, interpretation of
alterations in brain activity is difﬁcult (and sometimes im-
possible); we can only surmise that these changes may fa-
cilitate maintenance of normal performance. Furthermore,
when investigating populations with neurodegenerative dis-
ease one might postulate an additional indeterminate effect
of disease pathology on brain activity. Disease pathology
may not only directly affect brain activity in terms of com-
pensation, but may also exert subtle effects unrelated to
maintenance of behaviour. Thus, it is important when at-
tempting to operationalize compensation to try and ac-
count for pathological burden and be aware of its
potential impact on the measurement of variables.
A recent review identiﬁed three components necessary to
characterize compensation in ageing: extent of pathology,
behavioural performance, and a measure of brain activity,
such as signals derived from functional MRI measurements
(Dennis and Cabeza, 2013). ‘Successful compensation’ was
identiﬁed as a positive relationship between task perform-
ance and functional MRI signals, modiﬁed by age-related
neuronal alterations. This model could be extended to
Operationalizing compensation BRAIN 2017: 140; 1158–1165 | 1159
characterize compensation in neurodegeneration. However,
it does not directly account for concomitant changes in
pathology across individuals during the course of neurode-
generative disease. To quantify compensatory behaviour ef-
fectively in neurodegeneration, not only should the
functional MRI signal as a marker of brain activation
and network-relevant task performance be explored, but
it should be examined across a spectrum of pathology.
We hypothesize that compensation occurs in cases where
increased brain activation is needed to maintain normal
levels of behaviour in the presence of structural loss.
Eventually pathology becomes too severe resulting in be-
haviour as well as brain activation decreasing with struc-
ture over time.
An illustration of our hypothesized underlying model is
shown in Fig. 1. The crucial components of compensation
are a performance outcome (Y), an activation signal com-
pensator (C) (e.g. functional MRI signal), and brain volume
(X) (as a proxy for disease load). The horizontal axis rep-
resents time (or age of the participants), and the vertical
axis represents scores on measures standardized to have
equal means at the ﬁrst observation. Curves indicate
change over time for brain activity, performance, and
brain volume. Three phases are depicted by the vertical
dashed lines: Phase 1 spans (T0,T1), Phase 2 spans
(T1,T2) and Phase 3 spans (T2,T3). In neurodegenerative
disease, disease load is expected to steadily increase over
time regardless of phase. Phase 1 is compensation, as brain
activation (C) increases in reaction to brain deterioration
(X), and performance (Y) is maintained. In Phase 2, disease
effects start to overwhelm compensation, activation plat-
eaus, and performance starts to deteriorate. Phase 3
shows relentless disease effects, brain activation decreases
and there is acceleration in the deterioration rate of per-
formance. The curves are idealized; there might be several
stages where phasic change is monotonic rather than linear,
and turns at the thresholds may be gradual rather than
sharp. The important point to appreciate from Fig. 1 is
that compensation leads to speciﬁc long-term patterns of
change over time for three key variables.
We recently examined compensation in the TrackOn-
HD cohort using a novel cross-sectional model of compen-
sation incorporating Huntington’s disease severity, func-
tional MRI brain activity and task performance data
(Kloppel et al., 2015). Results showed an asymmetric pat-
tern of compensation within the cognitive network with
evidence of a compensatory effect located in the right hemi-
sphere, but little evidence of any compensation in the left
hemisphere or in the motor network.
For cross-sectional studies, there is a degree of uncer-
tainty regarding existing individual levels of performance,
brain activity and structural load, and these ﬁndings can
only suggest evidence of compensation (Raz and
Lindenberger, 2011). To understand compensation in
Huntington’s disease (or other neurodegenerative diseases)
more fully, it is necessary to follow individuals over time.
Little is understood regarding how compensatory mechan-
isms change over time and how they should be measured.
Longitudinal models may help us to identify at what point
along the disease trajectory compensatory behaviours
change and eventually fail. We hypothesize that longitu-
dinal compensation occurs when increases in brain activa-
tion over time are needed to maintain normal levels of
behaviour as neuronal loss progresses. The longitudinal ap-
proach will be an extension of the cross-sectional model, so
we begin with a consideration of compensation in the single
time point scenario.
Visualizing cross-sectional
compensation
Visualization is a powerful tool for the analysis and inter-
pretation of compensation patterns. Consider the case of a
cross-sectional study where all the data are collected at a
single time point. In terms of the underlying model (Fig. 1),
the time dimension is eliminated and disease effects are
inferred from differences in brain volumes among individ-
uals. Patterns caused by compensation must be assessed
using individuals sampled from the time or age spectrum.
To provide examples throughout, we simulated longitu-
dinal population data (n = 10 000) based on the model of
Figure 1 Underlying compensation model showing change
in key variables over time (activation, performance, brain
volume). Measures are assumed to be standardized to have the
same mean value at the first time point. Three phases are defined by
the thresholds at T1 and T2 (dashed vertical lines). Phase 1 spans
(T0, T1), Phase 2 spans (T1 to T2), and Phase 3 spans (T2 to T3).
Phase 1 illustrates compensation in which brain volume decreases,
activation increases, and performance is maintained. Phase 2 indi-
cates that disease effects are beginning to overwhelm compensation,
as activation flattens and performance begins to decrease. Phase 3
shows the complete swamping of compensation by disease effects
with all three variables decreasing.
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Fig. 1. A time series with 21 regular visits was generated
for each individual with a random intercept term to ac-
count for dependency due to repeated measures, and a
random error term to account for chance perturbations;
for model details see Supplementary material. To simulate
the sampling of cross-sectional data, we randomly selected
n = 200 hypothetical participants from the population, and
randomly chose one time point for each individual.
Figure 2 shows the sampled points using a scatterplot in
which the variables are plotted as a function of age, with
age being a cross-sectional variable here because there is
only one age per hypothetical participant. Smooth curves
(local scatterplot polynomial smoothing) were ﬁt for
each variable in isolation. The patterns of the smooth
curves are reminiscent of the curves of the underlying
model (i.e. Fig. 1).
Modelling cross-sectional
compensation
In addition to visualization, statistical models might be
used to assess the consistency of sample data with the
underlying compensation patterns and phases of Fig. 1.
The underlying model speciﬁes that the performance trajec-
tory over age (time) is determined by disease load (brain
volume) and the compensator variables (activation). One
approach for assessing the agreement of cross-sectional
sample data to the underlying theoretical patterns is to ﬁt
separate regression models for each of the three variables.
Because the boundaries of the phases are generally
unknown, our approach is to model non-linearity with a
quadratic polynomial of age. Suppose that Yi is the per-
formance score for the ith participant ði ¼ 1; . . . ;NÞ, and
similarly for Xi and Ci. Then consistency with the Fig. 1
patterns can be assessed by estimating the following
models,
Xi ¼ 0 þ 1agei þ eXi; ð1Þ
Ci ¼ 0 þ 1agei þ 2age2i þ eCi; ð2Þ
and
Yi ¼ 0 þ 1agei þ 2age2i þ eYi; ð3Þ
where ei is random error and agei is age measured at one
time point for each person. Nuisance variables are omitted
here for clarity, but they may be added to each equation
for additional adjustment. For example, in Huntington’s
disease, which is caused by an expansion of the cytosine-
adenine-guanine (CAG) trinucleotide repeat, it is important
to adjust for the length of the CAG-repeat expansion be-
cause of its well-known inverse relationship to age at motor
onset (Ross and Tabrizi, 2011).
Suppose that there is adequate age representation to
detect long-term patterns. Then the following parameter
values are consistent with compensation patterns: 150
(volume constantly decreasing), 250 (activation having
a concave-downward pattern), and 250 (performance
having a concave-downward pattern). The Equation 1–3
parameters can be estimated with multiple regression
using ordinary least-squares and inference is predicated
on the assumptions of normally distributed and homoge-
neous error. A one-sided t-test can be used to evaluate the
null hypothesis that each parameter is equal to zero, with
the alternative hypothesis that a parameter is less than zero.
These tests, along with visualization, are the primary means
of assessing consistency of cross-sectional data with long-
term compensation effects.
Additional inferences are possible if one is willing to
assume that Equations 1 and 2 are true models, rather
than just approximations for the Fig. 1 patterns. We hy-
pothesize that Y is determined by X and C allowing for
random error. It follows that Equation 3 is a linear com-
bination of the ﬁrst two equations Yi ¼ Xi þ Ci þ eYi. The
equivalence implies 0 ¼ a0 þ 0, 1 ¼ 1 þ 1, and
2 ¼ 2. The latter two equivalencies are most important
for compensation, and a conﬁdence interval for the differ-
ence of parameters can be computed based on the sample
estimates; that is, a conﬁdence interval for 1  ð1 þ 1Þ
and a conﬁdence interval for 2  2. Evidence for com-
pensation patterns is provided when 0 is contained in each
conﬁdence interval, indicating the sample difference is not
statistically reliable. A more lax criterion for consistency
with the compensation of Fig. 1 is that the second
conﬁdence interval does not contain negative values.
Figure 1 implies that the quadratic coefﬁcient should be
stronger for C (greater downward concavity), so that
Figure 2 Visualization of simulated cross-sectional data (n
= 200) with three key variables (activation, volume, per-
formance). Scatterplot of values by age, with age being measured
at only one time point per person. The measures were standardized
to have the same mean at the first age. The smooth lines are based
on a local polynomial smoother applied separately for each
measure.
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242. Similarly, 1 is the sum of a positive value (1)
and a negative value (1) so that 141, which can also be
evaluated with a conﬁdence interval.
A method for simultaneously estimating all parameters
with ordinary least-squares and using standard errors
based on the covariance of the parameters is provided in
the Supplementary material. More sophisticated approaches
are possible, such as estimating the phase thresholds based
on visualization, for example, and then using piece-wise or
spline models of age for the C and Y regression models
(X has a constant decrease and does not need splines).
Visualizing longitudinal
compensation
Using cross-sectional data to make inferences about a lon-
gitudinal process is not optimal. Valid inferences depend on
the extent to which individuals of different ages accurately
represent the general process that all people experience over
time. This exchangeability is not plausible when there are
cohort effects, such as when a new treatment is only avail-
able to young patients. Furthermore, between-individual
variability tends to be larger than within-individual vari-
ability, often resulting in higher statistical power for testing
effects when participants are measured over time. For these
reasons, longitudinal data are preferred for examining and
testing compensation patterns.
Longitudinal sample data are assumed to arise when in-
dividuals are randomly sampled from a population (here
with neurodegenerative disease) and their responses are re-
corded over time. This process was simulated by randomly
sampling n = 200 individuals from our generated
population and randomly selecting three consecutive time
points from the 21 available. Assuming the symbols in Fig.
1 represent observations at annual visits, the simulated
sample data represent a 3-year observational study in
which participants vary extensively on their age at entry.
Figure 2 can be used for visualization, but this ignores the
serial nature of the data. More appropriately, a spaghetti
plot can be constructed in which the repeated measures of
each participant are connected by lines. Figure 3 shows the
spaghetti plot for the simulated sample data, with the meas-
ures panelled to facilitate interpretation. Variability among
individual trajectories is apparent due to the random effect
and the random error, but the patterns are similar to Fig. 1.
A smooth curve can be ﬁtted among the individual trajec-
tories to characterize aggregate change, either with a scat-
terplot smoother or with the methods discussed below.
Modelling longitudinal compensation
When repeated measurements are available, it is natural to
extend the model of Equations 1–3 to a longitudinal con-
text. The approach here is to adopt the same model form as
Equations 1–3, but account for the correlation induced by
repeated measurements using random effects and an error
term for random perturbations. The general framework is
the linear mixed model (LMM).
Suppose that Yij is the performance outcome for the i
th
participant at the jth age (j ¼ 1; . . . ;TiÞ, with Ti ¼ T when
there are no missing data. Similarly for Xij and Cij, the
LMM version of the compensation pattern models are
Xij ¼ a0i þ 0 þ 1ageij þ eXij; ð4Þ
Figure 3 Visualization of simulated longitudinal sample data (n = 200, three time points) with three key variables (activation,
volume, performance). The spaghetti plots connect the three repeated measures for each individual with a line; each variable is depicted in a
different panel (same participants in each), and all the variables are standardized to have the same mean for the first age.
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Cij ¼ b0i þ 0 þ 1ageij þ 2age2ij þ eCij; ð5Þ
and
Yij ¼ g0i þ 0 þ 1ageij þ 2age2ij þ eYij: ð6Þ
Nuisance variables are again suppressed for clarity. In
Equations 4–6, age is now time-varying; the Greek letters
are ﬁxed effects that do not vary over time or participants;
the lower case Arabic letters (other than e) are individual-
speciﬁc random effects that vary over participants, but not
time (assumed to be normally distributed with zero-mean
and non-zero variance); and eij is random error (assumed to
be normally distributed with zero-mean and constant vari-
ance over time). The variance-covariance matrix among the
times (ages) for the outcome variable is a function of the
variance components of the random effects and error. The
single random effect results in a constant covariance be-
tween any two time points, but additional random effects
can be speciﬁed to provide a richer structure (Verbeke,
2000).
Similar to the cross-sectional context, long-term patterns
consistent with compensation would have 150 (volume
constantly decreasing), 250 (activation having a con-
cave-downward pattern over time), and 250 (perform-
ance having a concave-downward pattern over time).
A method for simultaneously estimating the parameters
of Equations 2–4 is provided in the Supplementary mater-
ial. Maximum likelihood methods are used with LMM,
allowing similar tests of estimated coefﬁcients and conﬁ-
dence intervals as in the cross-sectional case.
Discussion
The longitudinal compensation models proposed here are
ﬁrst attempts at operationalizing compensation over time.
We argue that to analyse compensatory mechanisms, it is
necessary to model changes in brain activity and disease
load (pathological severity), which are thought to inﬂuence
changes in performance. Incorporating structural measures
of disease load within the compensation model allows an
index of disease progression and an account of variability
in structural degeneration. Combining disease load with
brain activation and performance constitutes novel longitu-
dinal compensation models that provide a means for em-
pirical testing of longitudinal compensation in
neurodegeneration.
There are some considerations and potential limitations
to longitudinal compensation modelling. First, our ex-
amples of simulated sample data are idealized; we ran-
domly sampled individuals from the entire spectrum of
the critical age epoch to illustrate compensation patterns.
Restricting the age (or disease load) range has implications
for the statistical compensation models. For example, if
participants are only sampled from Phase 1 of our
underlying model (Fig. 1), the regression coefﬁcients
might be severely attenuated relative to sampling from the
entire range. Under the Phase 1 sampling scenario, non-
linear effects probably cannot be detected and performance
does not vary over time and cannot covary with age (or
activation or disease load). If only Phase 3 participants are
sampled, the linear age effects might be very strong, but
again the non-linear effects indicative of long-term compen-
sation probably cannot be detected. In planning a study or
analysing data from an existing database, it is important to
assess the extent of sampling over the critical epoch in
which compensation patterns are expected to emerge. For
example, in Huntington’s disease research, the critical
epoch is from the pre-manifest stage (prior to motor diag-
nosis) to early Huntington’s disease (up to a few years post
motor diagnosis). As Huntington’s disease is a relatively
slow progressing disease, it is important to sample both
pre-manifest and early Huntington’s disease participants
to increase the likelihood of detecting patterns of the
hypothesized underlying model. Similar considerations
apply for other diseases.
Variable transformations must be carefully considered
when studying compensation. Transformations are routine
in many research areas; examples include scaling a brain
substructure volume (e.g. putamen volume) by intracranial
volume (ICV), and scaling a performance measure based on
an underlying item response theory model (e.g. the Rasch
model). Our compensation model assumes particular linear
and curvilinear functional forms for variables over time.
Non-linear transformations of variables applied at each
time point can induce inconsistency with the patterns of
Fig. 1, even though the untransformed trajectories have
the exact patterns over time. For example, a constant de-
crease in putamen volume is consistent with our underlying
model. Putamen volume divided by baseline ICV is ex-
pected to have a constant decrease over time because div-
ision (multiplication) is a linear transformation. On the
other hand, non-linear corrections for ICV have been sug-
gested, such as putamen volume divided by baseline ICV
taken to the bth power (i.e. ICVb, where b =2f0;1g) (Liu
et al., 2014). Such transformations may induce a curvilin-
ear decrease over time, which is inconsistent with our
underlying model (there may be monotonic decrease but
not linear decrease). It is possible to sketch expected com-
pensation trajectories of transformed variables over time.
However, the graphical and statistical methods for examin-
ing the extent of compensation might vary from the ones
discussed here.
Although we think the examination of compensation can
be performed with the graphical methods discussed, it is
acknowledged that statistical testing is widespread. In the
statistical evaluation of compensation, sample size and the
number of repeated measures should be considered when
testing effects and computing conﬁdence intervals. Sample
size can have potentially opposite effects on the assessment
of compensation patterns, depending on the method that is
used. If linear and quadratic coefﬁcients are tested for
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signiﬁcance in either Equations 1–3 or 4–6, then a larger
sample size will increase statistical power and increase the
likelihood of rejecting null hypotheses of non-compensation
(all other things being equal). On the other hand, if conﬁ-
dence intervals of differences of parameters are computed,
then a large sample size will cause smaller intervals (other
things being equal) and potentially small clinical differences
can become signiﬁcant statistical differences. To address
this issue, it would be helpful to have a threshold based
on an important clinical difference. However, deﬁning
such a threshold is challenging. Another consideration for
our simulation is that the error variance and random ef-
fects variance were deliberately small in order to illustrate
compensation patterns. Real sample data may be
nosier and may not have the orderliness depicted in our
graphs.
While there is evidence that neuronal degeneration be-
comes increasingly widespread anatomically as disease pro-
gresses, there may be a high level of individual variability in
the rate of change of degeneration. Although this may be a
negligible consideration for observation periods that are
short relative to disease evolution, it might considerably
impact the change in compensatory processes between in-
dividuals, such that one individual may deteriorate signiﬁ-
cantly faster than another with comparable baseline disease
load and functional MRI activity. Our longitudinal statis-
tical model (Equations 4–6) accounts for individual vari-
ability of initial levels (i.e. random intercepts), but it may
be necessary to add random effects for linear and quadratic
terms in order to adequately account for the variation. It
should be noted that adding random effects will increase
estimation complexity, and large sample sizes may be ne-
cessary for proper inferences.
The simulated longitudinal data (Fig. 3) depict the situ-
ation in which many individuals are tracked for a rela-
tively short time. To increase the likelihood of avoiding
potential cohort effects and to better understand longitu-
dinal evolution, it is desirable to sample fewer individuals,
but follow them for a long time (e.g. 10 years).
Typical study resources do not allow for follow-up of
more than a few years, so sampling approaches should
be devised to ensure adequate between-individual
differences.
It is also important to note that while we have focused
here on brain volume as a measure of disease load in neu-
rodegeneration, the compensation models we present can
easily be adapted to include alternative measures of disease
load or ones that are most appropriate for the disorder
being examined. For example, while structural volume is
the most robust measure for Huntington’s disease progres-
sion, the boundary shift integral, a measure of cerebral
volume change, could also be used as an alternative meas-
ure of disease load (Freeborough and Fox, 1997). This also
applies to measures of brain activity where electrophysio-
logical measures or other MRI measures could replace
functional MRI signals.
Conclusion
Compensation is proposed to account for the dissociation
between progression of neuronal pathology and absence of
behavioural changes in the early stages of neurodegenera-
tion. Here, we have provided a framework for the opera-
tionalization of compensation. The focus of analysis—both
statistical modelling and visualization—is on patterns of
change caused by compensation over a critical epoch.
Although these are not the only possible models of longi-
tudinal compensation, we propose that the ﬁeld should
adopt a more systematic approach to operationalizing
and investigating compensation using similar theoretical
and operational approaches to those included here.
Acknowledgements
The authors thank the TrackOn study participants, the
CHDI/ High Q Foundation, a not-for-proﬁt organization
dedicated to ﬁnding treatments for Huntington’s disease
and Richard Frackowiak, Nellie Georgiou-Karistianis,
Christoph Kaller, Karl Friston, Nikolaus Weiskopf, Daniel
S. O’Leary and Stephane Lehericy for helpful advice.
Track-On investigators:
A. Coleman, J. Decolongon, M. Fan, T. Koren, B. Leavitt
(University of British Columbia, Vancouver); A. Durr, C.
Jauffret, D. Justo, S. Lehericy, K. Nigaud, R. Valabre`gue
(ICM and APHP, Pitie´- Salpeˆtrie`re University Hospital,
Paris); R. Roos, E. P. ‘t Hart, A. Schoonderbeek (Leiden
University Medical Centre, Leiden); C. Berna, H.
Crawford, R. Ghosh, D. Hensman, E. Johnson, M.
Desikan, P. McColgan, J. Read, G. Owen (University
College London, London); D. Craufurd (Manchester
University, Manchester); R. Reilmann, N. Weber (George
Huntington Institute, Munster); I. Labuschagne (Monash
University, Melbourne); G. B. Landwehrmeyer, I. Mayer,
M. Orth (University of Ulm, Ulm).
Funding
This work was funded by the CHDI Foundation, the
Wellcome Trust (GR), and the Medical Research Council
(SJT, MP) and supported by the National Institute for
Health Research (NIHR) University College London
Hospitals (UCLH) Biomedical Research Centre (BRC).The
main study sponsor (CHDI_Foundation) contributed to the
conception of the study and the study design but was not
responsible for data collection, data analysis, data interpret-
ation, or writing of the report.
Supplementary material
Supplementary material is available at Brain online.
1164 | BRAIN 2017: 140; 1158–1165 S. Gregory et al.
References
Barulli D, Stern Y. Efﬁciency, capacity, compensation, maintenance,
plasticity: emerging concepts in cognitive reserve. Trends Cogn Sci
2013; 17: 502–9.
Dennis NA, Cabeza RE. Frontal lobes and aging: deterioration and
compensation. In: Stuss DT, Knight RT, editors. Principles of frontal
lobe function. . New York, NY: Oxford University Press;2013.
p. 628–52.
Freeborough PA, Fox NC. The boundary shift integral: an accurate
and robust measure of cerebral volume changes from registered
repeat MRI. IEEE Trans Med Imaging 1997; 16: 623–9.
Klo¨ppel S, Gregory S, Scheller E, Minkova L, Razi A, Durr A, et al.
Compensation in preclinical Huntington’s disease: evidence from the
TrackOn-Hd study. EBioMedicine 2015; 2: 1420–9.
Liu DW, Johnson HJ, Long JD, Magnotta VA, Paulsen JS. The power-
proportion method for intracranial volume correction in volumetric
imaging analysis. Front Neurosci 2014; 8: 356.
Lo¨vde´n M, Ba¨ckman L, Lindenberger U, Schaefer S, Schmiedek F. A
theoretical framework for the study of adult cognitive plasticity.
Psychol Bull 2010; 136: 659–76.
Malejko K, Weydt P, Su¨ßmuth SD, Gro¨n G, Landwehrmeyer BG,
Abler B. Prodromal huntington disease as a model for functional
compensation of early neurodegeneration. PLoS One 2014; 9:
e114569.
Obeso JA, Rodriguez-Oroz MC, Lanciego JL, Rodriguez Diaz M.
How does Parkinson’s disease begin? The role of compensatory
mechanisms. Trends Neurosci 2004; 27: 125–7; author reply 127–8.
Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC. The cognitive burden
in Huntington’s disease: pathology, phenotype, and mechanisms of
compensation. Mov Disord 2014; 29: 673–83.
Raz N, Lindenberger U. Only time will tell: cross-sectional studies
offer no solution to the age-brain-cognition triangle: comment on
Salthouse (2011). Psychol Bull 2011; 137: 790–5.
Reuter-Lorenz PA, Park DC. How does it STAC up? Revisiting the
scaffolding theory of aging and cognition. Neuropsychol Rev 2014;
24: 355–70.
Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogen-
esis to clinical treatment. Lancet Neurol 2011; 10: 83–98.
Scheller E, Minkova L, Leitner M, Klo¨ppel S. Attempted and success-
ful compensation in preclinical and early manifest neurodegenera-
tion—a review of task FMRI studies. Front Psychiatry 2014; 5: 132.
Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc
Disord 2006; 20: 112–17.
Verbeke G, Molenberghs G. Linear mixed models for longitudinal
data, Vol. 1. New York, NY: Springer-Verlag; 2000.
Operationalizing compensation BRAIN 2017: 140; 1158–1165 | 1165
